Novartis to acquire Myricx Bio for $1.5 Billion
On Jul. 6, 2026, Novartis announced it has reached an agreement to acquire Myricx Bio for up to…
-
-
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
On Jun. 24, 2026, Antares Therapeutics announce it has entered a collaboration with Novartis that could be worth…
-
Roche announces global collaboration with Nurix Therapeutics worth up to $2.3 billion
On Jun. 7, 2026, Roche announced that it has entered into an exclusive licensing and collaboration agreement with…
-
Microrobots repair spinal cord
On Jun. 2, 2026, a research team from ETH Zurich and the University of Zurich (UZH) announced it…
-
Roche agrees to acquire US-based PathAI for $1 Billion
On May 6, 2026, Swiss pharmaceutical giant Roche announced it had agreed to acquire U.S.-based digital pathology and…
-
Study Reports unprecedented view of the immune system’s killer cells
On May 4, 2026, a study conducted by the University of Geneva and the Lausanne University Hospital (CHUV)…
-
UCB to acquire Candid Therapeutics for more Than $2 Bllion, building upon its existing immunology pipeline
On May 3, 2026, UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it…
-
Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation
On Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE…
-
Novartis to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline for $3 Billion
On Mar. 20, 2026, Novartis announced an agreement with Synnovation Therapeutics, to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor,…
-
Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago
On Feb. 24, 2026, The family of a Baltimore woman whose cells were extracted for medical research without…
-
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
On Feb. 6, 2026, Novartis broke ground on a new, state-of-the-art global Biomedical Research center in San Diego,…
-
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida
On Jan. 9, 2026, Novartis announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in…
-
Novartis and U.S. government reach agreement on lowering drug prices
On Dec. 19, 2025, Novartis, a leading global innovative medicines company, announced it has reached an agreement with…
-
Novartis announces plans to build flagship manufacturing hub in North Carolina
On Nov. 19, 2025, Novartis, a leading global innovative medicines company, announced plans to expand its operations in…
-
Biotechnology | Disease | FDA | Therapeutics
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
On Nov. 17, 2025, Sandoz announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by…
-
Novartis to acquire Avidity Biosciences, an innovator in RNA therapeutics for $11 Billion
On Oct. 26, 2025, Novartis announced that it has entered into an agreement to acquire Avidity Biosciences, a…
-
Setback for Roche in Natco Pharma case as India Supreme Court allows generic drug sales
On Oct. 18, 2025, the Swiss Pharma giant F Hoffmann La Roche (Roche) suffered a setback as the…
-
Novartis to acquire Tourmaline Bio and pipeline for atherosclerotic cardiovascular disease, valued at $1.4 Billion
On Sept. 9, 2025, Novartis announced that it has entered into an agreement to acquire Tourmaline Bio, a…
-
ETH Zurich Computer Scientists Create A ‘DNA search engine’
On Aug. 10, 2025, computer scientists at ETH Zurich announced they have developed a digital tool capable of…
-
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub
On May 12, 2025, Roche announced it plans to invest up to $550 million in its Diagnostics site…
-
Dangerous fungal spores can surf the stratosphere—and survive
On May 7, 2025, scientists reported that they have captured fungal spores cruising in the inhospitable environment of…
-
Roche to invest $50 billion in pharmaceuticals and diagnostics in the U.S. over the next five years
On Apr. 22, 2025, Roche announced that it will invest USD $50 billion into the United States in…
-
Novartis to expand US-based manufacturing and R&D footprint with investment of $23B over the next 5 years
On Apr. 10, 2025, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over…
-
WHO prequalifies the first self-test for hepatitis C virus
On Jul. 10, 2024, The World Health Organization (WHO) announced it had has prequalified the first hepatitis C…
-
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA EUA
On Jun. 10, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) had granted Emergency Use…
-
WHO reported Person with bird flu died in Mexico
On Jun. 5, 2024, the World Health Organization (WHO) reported that a person with prior health complications who…
-
Biotechnology | Disease | FDA | Oncology | Women's Health
Roche announced FDA approval of HPV self-collection solutions in the U.S. , expanding screening to help eliminate cervical cancer
On May 14, 2024, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus…
-
Roche received FDA approval for the first molecular test to screen for malaria in blood donors
On Mar. 26, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) had approved the cobas…
-
Novartis received FDA approval for Fabhalta (iptacopan) as the first oral monotherapy for adults with PNH
On Dec. 5, 2023, Novartis announced that the U.S. Food and Drug Administration (FDA) had approved Fabhalta (iptacopan)…
-
FDA approved Novartis Cosentyx as the first new biologic treatment for hidradenitis suppurativa patients in a decade
On Oct. 31, 2023, Novartis announced that the US Food and Drug Administration (FDA) had approved Cosentyx (secukinumab)…
